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A B S T R A C T   
The majority of people receiving treatment for their heroin addiction, are prescribed methadone; for which there 
is an extensive evidence base. When treatment starts, people take their daily dose of methadone under super-
vision at a community pharmacy. Supervision guarantees methadone is taken as directed by the individual for 
whom it has been prescribed, helps to ensure individuals take their correct dose every day, and safeguards 
against diversion and overdose. However, individuals often fail to attend the pharmacy to take their methadone. 
Each missed dose is of concern. If a patient misses their daily dose of methadone, they will start to experience 
opiate withdrawal and cravings and are more likely to use heroin. If they miss three days dose, there are concerns 
that they may lose tolerance to the drug and may be at risk of overdose when the next dose is taken. Hence there 
is an urgent need to develop effective interventions for medication adherence. Research suggests that incentive- 
based medication adherence interventions may be very effective, but there are few controlled trials and the 
provision of incentives requires time and organisational systems which can be challenging in pharmacies. The 
investigators have developed the technology to deliver incentives by mobile telephone. This cluster randomised 
trial will test the feasibility of conducting a future trial evaluating the clinical and cost effectiveness of using 
telephone delivered incentives (praise and modest financial rewards via text messaging) to encourage adherence 
with supervised consumption of methadone in community pharmacies. Three drug services (each with two or 
three community pharmacies supervising methadone consumption that will enrol 20 individuals, a total of 60 
participants) will be recruited and randomly allocated to deliver either i) telephone delivered incentives, ii) 
telephone delivered reminders or iii) no telephone system. Acceptability, recruitment, follow-up, and suitable 
measures of clinical and cost effectiveness will be assessed. Findings from this feasibility study will be assessed 
against stated progression criteria and used to inform a future confirmatory trial of the clinical and cost effec-
tiveness of telephone delivered incentives to encourage medication adherence. 
Trial registration: ISRCTN58958179 (retrospectively registered).   
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1. Introduction 
Heroin addiction is a major public health issue. In 2011/12, there 
were an estimated 256,000 heroin (and other opiates) users in England 
[1]. Heroin and other opiates are responsible for more than 50% of all 
drug overdose deaths in England [2]. The costs to society of Class A drug 
use (including heroin use) were an estimated £15.4 billion in 2003/04 
[3]. In 2012, there were approximately 155,000 people in treatment for 
heroin (or opiate) addiction in England. The majority are prescribed 
opiate substitution treatment (OST) with methadone or buprenorphine 
[4] for which there is an extensive evidence-base [5,6]. The National 
Institute for Health and Care Excellence (NICE) recommend substitute 
prescribing as the most effective treatment, alongside psychological 
therapies [7]. However, recovery from heroin addiction is a long-term 
process and many heroin users relapse into heroin use leading to high 
attrition rates in OST [8]. The Department of Health recommends 
methadone and buprenorphine consumption is supervised in the early 
stages of treatment [9,10]. Supervision guarantees methadone is taken 
as directed by the individual for whom it has been prescribed; and helps 
to ensure individuals take their correct dose every day to mitigate 
withdrawal or craving. Moreover, supervision safeguards against 
diversion onto the illicit market and overdose. Supervision may be 
relaxed after a few months if stability and clinical progress can be 
demonstrated. Pharmacists play an important role in dispensing OST 
medication, with a network of community pharmacists across England 
providing local availability of medication. 
Individuals often fail to attend the pharmacy to take their medication 
and those who do are very likely to miss multiple doses. In 2005, over a 
two-week period, 13% of prescriptions for OST had at least one missed 
pick-up (day when patient had not attended to take their dose) [11,12]. 
Of these, 73% had one quarter of pickups missed and almost 19% had 
between one quarter and one half of pickups missed [11,12]. Also, 42% 
of OST patients at one London drug service had only partial or poor 
adherence to their medication in the previous 30 days, and more than 
one third of patients receiving supervised oral methadone had missed 
pick-ups [13]. For opiate patients it is important to take their medication 
every day, with each missed dose of concern. If a patient misses their 
dose it is likely that they will experience withdrawal symptoms and 
cravings which may lead them to use heroin. If they miss three dos-
es/days, there are concerns that they may lose their tolerance to the drug 
and be at risk of overdose when the next dose is taken. Clearly the 
success of any pharmacotherapy depends heavily on medication 
adherence and as noted, patients in OST are not achieving full patient 
benefit (abstinence from illicit drugs) due to non-adherence of medica-
tion. Furthermore, non-adherence to medication is associated with 
non-attendance at medical and psychosocial appointments [14,15]. A 
pharmacist (under local agreement with the drug clinic prescriber) is 
normally unable to dispense the next day’s dose if a patient has failed to 
pick-up for three consecutive days [9,16,17]. Of concern is the phar-
macists lack of consistent reporting to the prescribers about patient’s 
missed doses. Ten per cent of pharmacists stated that they would never 
or rarely report if a patient misses one or two doses to prescribers but 
would usually report if three doses were missed [11,12]. 
Therefore, there is an urgent need to develop effective interventions 
for medication adherence [18]. A recent Cochrane review of psycho-
logical interventions for enhancing medication adherence (medication 
for substance misuse treatment was not included in this review) 
concluded that only some improved adherence and none were effective 
in encouraging long term medication adherence [19]. 
Contingency management (CM), based on the principles of operant 
conditioning, involves the systematic application of positive reinforce-
ment to promote positive behaviour consistent with treatment goals and 
amplify patient benefit. CM in OST is effective at reducing illicit drug use 
[20,21], adherence to vaccination [22–24], HIV anti-retroviral and TB 
treatment [25–28]. NICE have recommended that CM be used in UK 
drug settings to target the reduction of drug use and encourage 
medication adherence [7,29]. A recent systematic review of studies 
using incentives to reinforce medication adherence concluded that 
incentive-based interventions are promising but understudied (this re-
view did not include OST studies) [30]. Effective methods to improve 
adherence need to be maintained for as long as the treatment is needed, 
requiring interventions that can be integrated into the care system in a 
cost-effective manner [19]. While CM requires time and organisational 
systems [31] which can be challenging in pharmacies dispensing to a 
high volume of patients, we believe CM delivered by technology might 
encourage medication adherence among individuals receiving OST 
while being resource light and cost-effective. While there is insufficient 
evidence to conclude that newer interventions such as text messaging 
reminders can improve adherence, there may be benefit to using text 
messaging in low-resource settings [19]. In a recent systematic review 
and meta-analysis of mobile telephone delivered CM interventions to 
promote behaviour change, CM delivered by mobile telephone was 
found to be effective at reducing tobacco and alcohol use. Only one 
study targeted medication adherence and this was to anti-retroviral 
medications among individuals with HIV and substance misuse [32]. 
The authors have developed a telephone system for delivering CM 
via text messages [33]. The study described in this paper aims to assess 
the feasibility of conducting a future confirmatory randomised 
controlled trial (RCT) of the clinical and cost-effectiveness of a telephone 
system for delivering text message incentives to encourage adherence to 
supervised oral methadone. 
2. Material and methods 
2.1. Aim 
This study aims to assess the feasibility of conducting a future 
confirmatory RCT of the clinical and cost-effectiveness of i) telephone 
delivered incentives (positive reinforcement through text messages and 
financial incentives) to encourage adherence to supervised oral metha-
done among individuals receiving opiate treatment, compared with ii) 
text message reminders or iii) no text messages. The intention is that the 
future confirmatory trial would also use a cluster randomised design. 
Within each cluster, all participants will receive the same allocated 
condition. We believe it is necessary that all patients attending the same 
drug service (and pharmacy) for supervised consumption of methadone 
receive the same supervised methadone consumption scheme (i.e. tele-
phone delivered incentives, reminders or neither) to ensure there is no 
risk of contamination by alternative treatments and eliminate possible 
patient self-selection by choosing pharmacies offering different schemes 
to receive their medication. 
The feasibility study has the following objectives: 1. Assess the 
willingness of clusters (drug services and allied community pharmacies) 
to be randomised; 2. Assess numbers of eligible patients relative to those 
screened, rates of recruitment and suitability of recruitment procedures; 
3. Assess rates of follow-up at 12 weeks; 4. Test accuracy of recording/ 
logging of attendance at the pharmacy; 5. Assess the acceptability of the 
study to patients; 6. Identify different options for quantifying the pri-
mary outcome (adherence to medication) for use in a future confirma-
tory trial and assess the utility and practicality of these options; 7. 
Characterise aspects of the primary outcome needed for a sample size 
calculation for a future confirmatory trial (e.g. For a continuous 
outcome, mean and standard deviation, an estimate of the intraclass 
correlation to inform a sensible range for the cluster trial design effect); 
and 8. Assess the most appropriate secondary outcome measures to 
determine patient benefit and cost-effectiveness, and 9. the availability 
and usefulness of existing data sets including existing pharmacy 
dispensing data sets. A process evaluation will be conducted alongside 
this feasibility trial to assess the acceptability of the intervention and the 
trial procedures and to determine how contextual factors and treatment 
process may impact on the primary outcome (attendance). Research 
ethics approval has been granted by London - South East Research Ethics 
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Committee (18/LO/1722). 
2.2. Design and setting 
This feasibility study will use a 3-arm cluster randomised controlled 
design (Fig. 1) where drug services and their allied community phar-
macists are the cluster. It is intended that this design will give us the 
feasibility information we need to determine whether it is possible to 
conduct a future confirmatory trial. 
Three sites (two National Health Service (NHS) substance misuse 
treatment services and one non-NHS) will be recruited from 4 sites 
approached. All sites will provide OST. This mix of non-NHS and NHS 
providers reflects current addiction service provision and will enhance 
the generalisability of the confirmatory study. At each site, two or three 
community pharmacies dispensing and supervising oral methadone to 
patients will be recruited. The criteria for enrolling community phar-
macies will include: Pharmacists are willing and able to provide six days 
supervised consumption of oral methadone; Pharmacy has a consulta-
tion room on the premises or a separate designated area on the 
dispensing counter in which participants can consume their oral meth-
adone under supervision; Pharmacy is currently providing supervised 
consumption of oral methadone to the patients at the drug clinic; 
Pharmacy is willing and able to provide dispensing records for partici-
pants over the 12-week intervention period. 
We will enrol eligible and consenting participants at entry to OST at 
the participating service. They will be provided with OST including 
daily (6 days a week) supervised oral methadone at their pharmacy for 
12 weeks and followed up at 12 weeks after enrolment. 
2.3. Characteristics of participants 
Participants will be those assessed for a new episode of OST at 
participating drug services (and will include either those newly pre-
senting to the service or those already attending the service and being re- 
assessed for OST having not receiving OST for at least 4 weeks). Inclu-
sion criteria for individual participants include: aged 18 years and over 
at enrolment; presenting to participating drug services for a new episode 
of OST (this excludes patients receiving a prescription for methadone or 
other opiate substitution medication within the last 4 weeks as well as 
those transferred from another service or prison); prescribed oral 
methadone; receiving supervised consumption of oral methadone from 
one of the participating pharmacies; receiving their supervised oral 
methadone six days a week; owns a mobile phone; and willing and able 
to provide informed consent. Therefore, they must be able to read En-
glish and not require the service of an interpreter. 
Patients will be excluded if they cannot read English or would 
require the service of an interpreter to understand a brief oral 
description of the study; they have already entered the trial; or they have 
previously attended the service (drug clinic) and were discharged within 
the last three weeks. 
2.4. Recruitment 
Twenty participants will be recruited at each site (drug service) over 
a three-month recruitment period between mid-December 2018 and 
mid-March 2019 by drug service staff, giving a total of 60 participants. 
Each individual presenting to the drug treatment clinic for a new episode 
of OST will be screened for eligibility. 
2.5. Processes/interventions and comparisons 
2.5.1. Interventions 
Opiate substitution treatment (OST). OST should be delivered in line 
with existing service protocols at sites. This would include psycho-social 
interventions usually delivered at the service. Each site will prescribe 
oral methadone for six days-a-week, with daily supervised consumption 
provided by a community pharmacy as part of usual treatment. 
Telephone system. The telephone scheme will be delivered for 12 
weeks in line with current clinical guidelines which recommend that 
individuals receive their methadone supervised at a community phar-
macy in the early stages of their treatment episode [10]. The telephone 
text message intervention will be discontinued if participants are no 
longer prescribed oral methadone or supervised consumption or they 
move to a non-participating drug service or pharmacy. 
The technology for telephone delivered incentives has already been 
developed by the authors, has been adapted and made operational for 
routine pharmacy use and has been piloted at two pharmacies. The 
technology uses internet-based software with an intelligent text message 
alert engine. It is hosted on and accessible through a secure website. The 
software will monitor all individuals and their supervised methadone 
appointments through an internet login on tablet computers at the 
pharmacy. The software is internet-based, thereby accessible from 
anywhere with an internet connection without the need to install and 
maintain separate standalone software. The internet-based software can 
contact individuals via mobile telephone text messages and keeps track 
of each time a patient logs in to attend a dosing appointment at the 
pharmacy, each time they do not log in to attend the appointment, and 
their monetary balance (if appropriate). The telephone system provides 
either:  
i. Telephone delivered incentives: Positive reinforcement through 
automated text messages of praise and modest financial incentives 
(CM), sent immediately after an individual logs in at their pharmacy 
(indicating they have taken their supervised methadone). Each time 
Fig. 1. Trial design.  
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a participant attends their pharmacy and consumes their supervised 
oral methadone they will receive a text message giving positive 
reinforcement (praise) and earn a small financial reward of 50p. If 
they attend for six days consecutively, they will earn a bonus reward 
of £5. The total possible financial reward is therefore £8/week or £96 
over 12 weeks. Participants will be paid directly through pre-paid 
debit cards (an automated reward payment platform) issued by the 
study team. These allow for financial incentives to be electronically 
loaded onto the participant’s card once satisfaction of the target 
behaviour has been verified. If they do not attend, participants will 
receive a “shaping message” that evening informing them that they 
can still earn 50p if they attend the pharmacy (and take their dose) 
the following day.  
ii. Telephone delivered reminders: Text message reminders sent in the 
morning and afternoon to attend the pharmacy and take their su-
pervised medication that day. Reminders will be sent each day for 12 
weeks (comparator group). 
with a third group that will not receive any telephone text messages. 
Participants in all groups (including those not receiving telephone 
messages) will use a self-service internet login at their pharmacy to re-
cord their attendance and consumption of methadone. Participants will 
not have access to the tablet to login until they have received their su-
pervised oral methadone. The telephone system also allows for the pa-
tients’ prescriber to receive weekly reports of their patient’s attendance 
and an early warning if their patient has missed two days. Prescribers for 
patients not receiving text messages will not receive these. 
The pharmacy will be unable to dispense the next day’s dose if a 
patient has failed to pick-up for three consecutive days. Therefore, the 
telephone system will be paused if a participant fails to attend their 
pharmacy and take their dose for three consecutive days. The telephone 
system will be re-instated when the pharmacy is able to dispense 
methadone again to the participant (after they have had their dose 
reassessed by their prescriber). 
OST will continue to be delivered to participants after 12 weeks. 
2.6. Outcome measures 
2.6.1. Feasibility outcomes  
(1) Enrolment rate of patients (Number enrolled per week, relative to 
those entering OST treatment, over the 12-week period);  
(2) Percentage of screened patients who are eligible for participation 
in the trial;  
(3) Percentage of eligible patients who consent to participation in the 
feasibility trial;  
(4) Percentage responding ‘yes’ to 12  weekly text message sent by 
researchers asking if they received all text message incentives or 
reminders for previous week (this will indicate whether they have 
mobile telephone and whether they are receiving text messages);  
(5) Accuracy of attendance measurement measured by percentage of 
matches between (a) daily pharmacy dispensing record and (b) 
record of attendance and medication compliance recorded in self- 
service internet login at the pharmacy. A ‘match’ is defined as 
agreement between (a) and (b) as to whether a participant 
attended their supervised methadone replacement appointment 
on a given day;  
(6) Number and percentage of participants followed-up for research 
interview at 12 weeks post enrolment, by arm, relative to those 
enrolled;  
(7) The willingness of drug services to participate - measured as the 
number and percentage of drug services enrolled relative to those 
approached;  
(8) The willingness of allied community pharmacies to participate - 
measured as the number and percentage of pharmacies enrolled 
relative to those approached;  
(9) Acceptability of the study to patients, drug service staff and 
pharmacists measured by qualitative views and experiences of 
patients, drug service staff and pharmacist. Focus groups will be 
held with between 5 and 8 participants at each service at a 
minimum of 10 weeks post enrolment. Interviews with drug 
service staff and pharmacists will be held at the end of the trial; 
2.6.2. Primary outcomes for exploration for a future confirmatory trial 
To look at the best ways to report missing doses/non adherence. 
Adherence to medication measured by (1) percentage of days during 12 
weeks post-enrolment when medication was taken; (2) Median number 
of days during 12 weeks post-enrolment when medication was not 
taken; (3) Likert scale categorising participants according to different 
levels of missed doses (number and percentage in each category), by 
arm"; and (4) Number of days to missed dose analysed using repeated 
events survival analysis. Adherence to medication will be calculated by 
(i) enumerating all days during each participant’s intervention period, 
(ii) removing inactive days (those when the participants were paused, 
off script, or not supervised), and (iii) determining their attendance as 
indicated in the pharmacy records. Data from daily pharmacy 
dispensing data sets will be the authoritative source on adherence to 
medication. 
Aspects of the primary outcome measures needed for a sample size 
calculation for a future confirmatory trial including (5) appropriate 
summary statistics (for example, mean and standard deviations for 
continuous outcomes); (6) estimate of the intraclass correlation (ICC) for 
the clusters. Information from three sites will provide an initial estimate 
of ICC, which will inform our sample size calculations for a larger trial. 
However, this estimate will be supplemented by information from pre-
vious studies with populations from primary care [34,35] and opiate 
substitution treatment [20, 21, 36] which suggest values of ICC less than 
0.05; and (7) qualitative information on the availability and usefulness 
of existing pharmacy dispensing data sets. 
2.6.3. Secondary outcomes of a future confirmatory trial 
(8) Number and percentage retained in treatment over the 12-week 
intervention period. Illicit drug use measured by Opiate Treatment 
Index (Section 2 – Drug Use) (Validated) [37] including: (9) Number and 
percentage using illicit street drugs in past 30 days; (10) Median number 
of days used illicit street drugs in past 30 days; (11) Median number of 
days injected illicit street drugs use in past month; (12) Route of use 
(number/percentage for each); (13) Average cost of each drug used on 
average day. (14) Alcohol Use Disorders Identification Test (AUDIT) 
(Validated, mean total score) [38]; (15) Hospital Anxiety and Depres-
sion Scale (HADS) (Validated, mean total anxiety and depression sub-
scale scores) [39]; (16) Social functioning measured using the Opiate 
Treatment Index (Validated, mean social functioning subscale score) 
[37]; (17) Physical and mental health status (Short form-36 subscale 
mean scores) [40]; and (18) Missing data by questionnaire and time 
point. 
2.6.4. Sociodemographic characteristics 
Age (mean and standard deviation); gender (number and percentage 
in each group); ethnicity (number and percentage in each group); 
employment status (number and percentage in each group); living sit-
uation (number and percentage in each group). 
2.6.5. Outcomes for economic evaluation 
Economic data collection measured by (1) Resource use schedules 
AD-SUS [41]; (2) EQ -5D-5L measure of health-related-quality of life 
[42]; and (3) the ICECAP-A measure of capabilities [43]. 
2.6.6. Process outcomes 
We will conduct focus groups with participants and interviews with 
participating drug service staff and pharmacists to assess (from each 
perspective) the acceptability of the intervention and the trial 
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procedures and also to determine how contextual factors and treatment 
process impact on feasibility criteria (including recruitment, take-up 
and compliance with assessments) the primary outcome (attendance). 
2.7. Participant timeline and study visits 
Participants will have a research assessment interview conducted by 
member of the research team at baseline and again at 12–14 weeks post- 
enrolment. (Fig. 2. Consort). The baseline assessment will be conducted 
at the earliest opportunity after the participant has consented. In addi-
tion to these interviews, towards the end of each participant’s inter-
vention period (minimum 10 weeks post-enrolment) the researchers will 
approach all participants enrolled in the trial (whether or not they 
continue to receive the trial intervention), drug service keyworkers 
(whose patients have participated in the study) and pharmacists to ask 
them if they would be willing to participate in focus groups and in-
terviews to provide information on their experience of taking part in the 
feasibility trial, using the tablet and receiving the telephone text mes-
sage incentives or reminders. 
2.8. Sample size 
One of the aims of this feasibility trial is to estimate parameters 
needed for a sample size calculation for a larger confirmatory trial. 
Therefore, at this stage, no formal sample size/power calculation was 
undertaken. 
2.9. Randomisation 
The three sites will be randomly allocated to one of the following 
three arms:  
A. Supervised Medication  telephone delivered text messages 
providing positive reinforcement and modest financial incentives;  
B. Supervised Medication  telephone delivered text messages 
providing reminders only; or  
C. Supervised Medication with no telephone text messages (Treatment 
as Usual). 
Fig. 2. Consort.  
N. Metrebian et al.                                                                                                                                                                                                                             
Contemporary Clinical Trials Communications 17 (2020) 100506
6
Using simple randomisation in a 1:1:1 allocation ratio, sequences 
will be generated using a random number generator. Given small the 
number of sites to be randomised, there will be no blocking, stratifica-
tion, or minimisation used in the randomisation procedures. 
2.10. Blinding 
Due to the nature of the intervention being studied, there will be no 
attempt at blinding either clinicians or participants. The researchers 
cannot be blinded due to the necessity to monitor the telephone system, 
with the analysing trial statistician unblinded in order to conduct the 
randomisation and monitor data. Only the senior trial statistician will be 
blind to treatment allocation throughout the study. 
2.11. Data collection and management 
There will be five forms of data collection: 
Firstly, researchers will conduct face-to-face interviews with partic-
ipants at baseline (after consent and immediately preceding enrolment 
onto the telephone system) and at 12 weeks post-enrolment. Interviews 
will be sought from all participants including those who discontinue 
receiving oral methadone treatment and/or discontinue receiving the 
telephone text message intervention as long as they do not withdraw 
consent for participation in feasibility trial/continued collection of their 
data. Participants will receive a £10 reimbursement for their time and 
travel for the baseline and follow-up interview. 
Secondly, the software system will collect information from partici-
pants via tablet computers in the pharmacies at each supervised meth-
adone appointment over the 12-week period. This will record a patient 
nickname and telephone number, the date and time, and whether they 
attended and consumed their methadone or not. These data will be 
stored on a secure web site. At the end of the 12-weeks intervention 
period, these data will be extracted from the software system by a 
research worker and entered into an SPSS database. This will be stored, 
along with other trial databases, with password protection on a secure 
KCL network drive. 
Thirdly, dispensing records kept by the allied pharmacies relating to 
trial participants will be provided to researchers after being pseudo- 
anonymised by the pharmacist (linked by nickname only). The phar-
macist will have participants’ names and nickname stored in a password 
protected file. 
Fourth, interviews and focus groups involving patients (including 
those who have discontinued receiving the telephone system and/or 
those who have discontinued receiving oral methadone treatment), 
staff, and pharmacists will be recorded by digital handheld audio 
recorder (with encryption facilities) and uploaded and stored on a 
password protected secure KCL network drive. Patient participants will 
receive a £10 reimbursement for their time and travel for the focus 
group. 
Data from the baseline (0 weeks) and follow-up (12 weeks) in-
terviews will be collected on paper case report forms (CRFs), which will 
be stored at KCL University. These data will be entered into SPSS da-
tabases by researchers at KCL University. Data from the telephone sys-
tem will also be exported into an SPSS database. The SPSS databases will 
be developed by KCL researchers and statisticians. Data entry will be 
undertaken by KCL researchers. Range checks will be used. Data entry 
will be checked against paper case report forms in 10% of participants to 
ensure accuracy of data entry, with higher order data queries under-
taken by the analysing statistician. SPSS databases will be stored on a 
KCL secure drive, and will be subject to version control to allow for an 
audit trail of database changes. Only members of the KCL research team 
will have access. Data extracts will be provided to the trial statistician 
upon request. Copies of the Pharmacy Dispensing records will be stored 
at KCL University. 
2.12. Data monitoring 
A Data Monitoring and Ethnics Committee (DMEC) will be convened. 
The DMEC will be responsible for data monitoring throughout this 
feasibility trial. Monthly recruitment progress will be reported and 
compared to recruitment targets at each DMEC meeting. Adverse events 
will also be reported at DMEC meetings, as detailed below. There are no 
interim analyses or audits of trial conduct planned. A Trial Steering 
Committee will be convened to provide independent expert advice on 
the ongoing conduct of the study. 
2.13. Data analysis 
A comprehensive statistical analysis plan will be developed and 
agreed with the trial’s oversight committees (DMEC and TSC). All data 
will be analysed using R 3.5 [44] with the exception of the economic 
evaluation, focus groups and qualitative interviews. 
The feasibility outcomes will be summarised with appropriate sum-
mary statistics (generally frequencies and proportions). Differences be-
tween arms, where appropriate, will be assessed by examining 
differences in proportions. Estimates will be provided with 95% confi-
dence intervals to provide an estimate of precision. 
The primary and secondary outcomes of a future confirmatory trial 
will also be summarised using appropriate statistics (e.g. mean and 
standard deviation/median and interquartile range for normally 
distributed/non-normally distributed continuous outcomes; counts and 
proportions for categorical outcomes). The outcome “number of days to 
missed dose” will likely be analysed using discrete-time survival analysis 
[45], although we may explore other methods. Differences between 
arms will be estimated as mean differences, difference in proportions, or 
by entering dummy variables into a regression model. Differences in 
survival outcome between arms will be expressed with hazard ratios. 
Associated confidence intervals will be estimated where appropriate. 
The primary purpose of these estimates is to inform sample size 
calculations of a future confirmatory trial. This analysis is not powered 
to detect differences between arms in the primary and secondary out-
comes of a future confirmatory trial. Therefore, these estimates will be 
treated as exploratory and not used as the basis for inferential state-
ments. These analyses will be done under the intention-to-treat princi-
ple. There will be no per-protocol or subgroup analyses. 
All efforts will be made to avoid missing baseline data (i.e. requiring 
completion of baseline data before randomisation), but if this occurs, 
missing values will be imputed according to current recommendations 
[46]. Missing scale item data will be handled as per questionnaire spe-
cific recommendations or, if no recommendations are available, 
pro-rating will be used (if less than 20% of items are missing the missing 
items will be replaced by the mean of the complete items). Given this is a 
feasibility study and the focus is not on between arm comparisons, 
multiple imputation for missing data will not be used. 
2.14. Economic data 
Data on health and social care service use will be collected using the 
Adult Service Use Schedule (AD-SUS), modified for use in substance 
misusing populations [41]. The feasibility of the AD-SUS will be 
explored based on completion rates, missing data (item missing, ques-
tionnaire missing), plausible values, and inconsistencies. Service use 
data will be presented as means with appropriate measures of dispersion 
together with the proportion of participants reporting each resource use 
item. We will use the EQ-5D-5L to measure health-related quality of life 
expressed as mean scores with appropriate measures of dispersion [47]. 
EQ-5D scores be calculated using 5L tariff and also the 3L tariff using the 
mapping function recommended by NICE [48]. We will also use the 
ICECAP-A to measure changes in participants capability to undertake 
activities important to them [49]. We will explore the feasibility of the 
EQ-5D-5L and ICECAP-A measures with sensitivity to changes in 
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comparable clinical outcomes (HADS, SF36 subscales) using appropriate 
measures of agreement. 
2.15. Process evaluation 
The qualitative process evaluation will generate evidence that sup-
ports refinement of the intervention and the proposed definitive trial. 
Specifically, we will assess (1) the acceptability of the intervention to 
participants (service-users) and clinicians; and (2) whether the inter-
vention can be implemented in routine practice and delivered by staff 
who have the necessary capacity and competencies, and (3) the 
acceptability of trial procedures. Our qualitative design will involve 
both interviews and focus groups. 
Interviews will be undertaken with pharmacists and prescribers to 
assess acceptability and satisfaction with telephone delivered incentives 
and reminders, the impact of monitoring and reporting medication 
compliance to prescribers, resources required, the organisational impact 
(both drug service and pharmacy), and factors which help or hinder fi-
delity. Sampling of pharmacists and prescribers will be purposive, with 
participants identified based on their relationship to the intervention 
and propensity to provide an important or distinct perspective (phar-
macists n  6; prescribers n  9). 
Focus-groups (n  6) will be used to obtain participant perspectives 
on using self-service internet-login, receiving telephone delivered in-
centives and reminders, debit card payments and trial procedures 
(notably randomisation and assessment procedures) We have opted for 
focus groups (as opposed to 1-2-1 interviews) because they are efficient 
in reaching numbers of participants and ensuring attendance. They also 
facilitate participant interaction that supports reflection on the pro-
cesses under study while (in this context) being low risk in terms of 
coverage of sensitive subject matter. 
All interviews/focus groups will be based on topic guides developed 
iteratively during the preceding study phases and applied flexibly to 
ensure coverage of key issues and responsiveness to emergent themes. 
Participants will be reimbursed £10 for attending a focus group. 
Interviews and focus groups will be audio recorded, transcribed 
verbatim and subject to a thematic analysis supported by NVIVO. The 
analysis will describe the different stakeholder experiences, and assess 
whether, how and to what extent, the professional, organisational and 
social contexts impacts on the delivery of the intervention and the 
acceptability and feasibility of trial procedures (particularly recruit-
ment, follow-up and outcome assessment). 
Data will support refinement of the confirmatory trial intervention, 
trial design and the scope and focus of the process evaluation which will 
run concurrently with the planned future confirmatory trial. 
2.16. Adverse event monitoring 
We will monitor all non-serious adverse events, serious adverse 
events, and serious adverse reactions to trial interventions, serious 
deterioration, and active withdrawals from treatment. Keyworkers and 
pharmacists will be asked to record events on a CRF and notify us if they 
are aware of any adverse events or active withdrawals from treatment. 
We will contact pharmacists and keyworkers once a week to monitor 
possible adverse reactions. These will be recorded in a specific SPSS 
database, stored on a secure KCL drive, and reported at each DMEC 
meeting. 
2.17. Progression criteria 
To proceed to a future confirmatory trial the following outcomes 
should be achieved. However, not achieving these criteria does not 
necessarily indicate unfeasibility of a future trial but underlines changes 
that need to be made to recruitment procedures, attendance record 
keeping and resources for follow-up. These include:  
 Recruitment of three drug services, two to three pharmacies and 60 
participants (20 from each drug service over 12 weeks);  
 50% of target patients (those patients presenting to participating 
drug services for a new episode of opiate substitution treatment 
(OST) who have not been receiving a prescription for methadone or 
other opiate substitution medication for >4 weeks and who have not 
been transferred in from another service or prison) eligible and 
consented.  
 >95% consistency in recording of pharmacy attendance (comparing 
daily pharmacy dispensing records vs. self-service internet login).  
 Rates of follow-up at 12 weeks (>70%).  
 Completion rates of economic data collection (>70%),  
 Missing data (item missing/questionnaire missing) (<10% missing 
data per questionnaire) and inconsistencies. 
3. Discussion 
The TIES feasibility study seeks to assess the feasibility of conducting 
a future trial of delivering a behavioural intervention by telephone to 
improve medication adherence. There is little work in this area. Findings 
from this study will be assessed against progression criteria to inform a 
future confirmatory trial. 
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